New: the shifts that come back across the latest research. See what to focus on

Horizon: now

Drug makers struggle to use AI with scattered data

Drug makers are adopting artificial intelligence to speed up production, but disconnected information across sites slows progress and limits success.

In the report's words: “Pharma manufacturers are moving from electronic production records to AI-assisted decisions, but disconnected data blocks progress.”p3–4

The number that matters

13%p2

life sciences executives seeing measurable AI improvement at scale

Where to focus

  1. 1Standardize batch definitions to quickly gather investigation evidence across systems.p2
  2. 2Centralize records, approvals, and exceptions to easily check batch release readiness.p14
  3. 3Create shared data definitions and standard processes to reuse AI across plants.p6–7

The details

Who it affects

Quality investigators and manufacturing leaders at large, multisite pharmaceutical manufacturers.p5, p7

What holds them back

  • Quality investigators struggle to investigate deviations quickly because they must manually gather evidence from systems with inconsistent batch definitions.p2
  • Quality reviewers struggle to assess batch release readiness because records, results, approvals and unresolved exceptions need checking across sources.p14
  • Manufacturing leaders struggle to reuse AI across plants because sites lack shared data definitions and standardized processes.p6–7

The numbers

  • Only 13% of 150 surveyed life sciences executives reported measurable AI improvement at scale.p2
  • AI was live and embedded in only 4 of 30 recorded manufacturing and quality use cases.p2

What people search for

  • speed up pharma deviation investigations
  • automatically gather batch investigation evidence
  • batch release checklist software
  • find missing batch release documents
  • connect pharma manufacturing data
  • roll out manufacturing AI across plants